Divi's Laboratories Limited
DIVISLAB.NS
Cena:
Valuace
15
Růst
45
Zdraví
80
Dokumenty & prezentace
Datum podání
2026
Výroční
Annual Report FY2026
15. čvc 2026
před 3 měs.
Výroční
As per enclosed letter.
25. kvě 2026
před 5 měs.
2025
Výroční
Annual Report FY2025
14. čvc 2025
před 1 r.
Výroční
As per enclosed letter.
17. kvě 2025
před 1 r.
Kvartální
as per enclosed attachment.
3. úno 2025
před 2 r.
2024
Kvartální
Submission of financial results for the quarter and half year ended September 30, 2024.
9. lis 2024
před 2 r.
Kvartální
As per enclosed letter.
3. srp 2024
před 2 r.
Výroční
Annual Report FY2024
15. čvc 2024
před 2 r.
Výroční
As per enclosed letter.
25. kvě 2024
před 2 r.
Kvartální
As per enclsoed attachment.
10. úno 2024
před 3 r.
2023
Kvartální
As per enclsoed.
6. lis 2023
před 3 r.
Kvartální
As enclsoed
14. srp 2023
před 3 r.
Výroční
Annual Report FY2023
2. srp 2023
před 3 r.
Výroční
as enclsoed
20. kvě 2023
před 3 r.
Kvartální
Further to our intimation dated January 23, 2023, we would like to inform that the Board of Directors of the Company at its meeting held on February 03, 2023 has, inter alia approved the ....
3. úno 2023
před 4 r.
2022
Kvartální
Further to our intimation dated October 28, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on November 07, 2022 has, inter alia, approved the ....
7. lis 2022
před 4 r.
Kvartální
Further to our intimation dated July 28, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on Friday, August 12, 2022 has approved the Unaudited ....
12. srp 2022
před 4 r.
Výroční
Annual Report FY2022
25. čvc 2022
před 4 r.
Výroční
As per enclosed.
23. kvě 2022
před 4 r.
Kvartální
Further to our intimation dated February 01, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on February 11, 2022 has, inter alia approved the ....
11. úno 2022
před 5 r.
2021
Kvartální
Further to our intimation dated October 28, 2021, we would like to inform that the Board of Directors of the Company at its meeting held on November 06, 2021 has, inter alia, approved the ....
6. lis 2021
před 5 r.
Kvartální
As enclosed.
7. srp 2021
před 5 r.
Výroční
Annual Report FY2021
2. srp 2021
před 5 r.
Výroční
As per enclosed.
29. kvě 2021
před 5 r.
Kvartální
We would like to inform that the Board of Directors of the Company at its meeting held on 06 February, 2021 has, inter alia, approved the Unaudited Financial Results for the quarter and ....
6. úno 2021
před 6 r.
2020
Kvartální
As enclosed.
7. lis 2020
před 6 r.
Výroční
Annual Report FY2020
19. srp 2020
před 6 r.
Výroční
As already informed vide our letter dated 17 August, 2020, the 30th Annual General Meeting (AGM) of the Company is scheduled to be held on Monday, 14 September, 2020 at 10.00 A.M. IST through ....
19. srp 2020
před 6 r.
Kvartální
As per attachment.
8. srp 2020
před 6 r.
Výroční
Further to our letter dated 30 May, 2020, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 06 June, 2020 has approved the Audited Financial ....
6. čvn 2020
před 6 r.
Kvartální
We would like to inform that the Board of Directors of the Company at its meeting held on 05 February, 2020 has, inter alia, approved the Unaudited Financial Results for the quarter and ....
5. úno 2020
před 7 r.
2019
Kvartální
Further to our intimation dated 25 October, 2019, we would like to inform that the Board of Directors of the Company at its meeting held on 05 November, 2019 has, inter alia, approved the ....
5. lis 2019
před 7 r.
Kvartální
Further to our intimation dated 01st August 2019, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 10th August 2019 has approved the Un-audited ....
10. srp 2019
před 7 r.
Výroční
Annual Report FY2019
25. čvc 2019
před 7 r.
Výroční
Board of Directors has approved the Audited Financial Results for the quarter and year ended 31st March, 2019. Board has recommended dividend @ 800% i.e Rs. 16/- per equity share of face ....
25. kvě 2019
před 7 r.
Kvartální
In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following: 1. Un-audited Standalone Financial ....
2. úno 2019
před 8 r.
2018
Kvartální
Further to our letter dated 19th October, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 27th October 2018 has approved Un-audited ....
27. říj 2018
před 8 r.
Kvartální
Further to our letter dated 23rd July, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 4th August 2018 has approved Un-audited ....
4. srp 2018
před 8 r.
Výroční
In continuation with the Audited Standalone and Consolidated Financial Results for the year ended 31st March, 2018 submitted with the Stock Exchanges on 26th May, 2018, we hereby attach ....
26. kvě 2018
před 8 r.
Kvartální
Further to our letter dated 18th January, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 27th January 2018 has approved Un-audited ....
27. led 2018
před 9 r.
2017
Kvartální
Further to our letter dated 20th October, 2017, we would like to inform that the Board of Directors of the Company at its meeting held on Tuesday, 31st October 2017 has approved Un-audited ....
31. říj 2017
před 9 r.
Kvartální
Further to our letter dated 14th July, 2017, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 22nd July 2017 has approved Un-audited Financial ....
22. čvc 2017
před 9 r.
Výroční
Further to our letter dated 15th May, 2017, we would like to inform that the Board of Directors of the Company at its meeting held on Friday, 26th May 2017 has approved the Audited Financial ....
26. kvě 2017
před 9 r.
Kvartální
Divis Laboratories Ltd has announced the following Unaudited Standalone results for the Quarter ended December 31, 2016 The Company has posted a net profit of Rs. 2683.20 million ....
4. úno 2017
před 10 r.
2016
Kvartální
Divis Laboratories Ltd has announced the Unaudited Standalone results for the quarter ended September 30, 2016 The Company has posted a net profit of Rs. 2238.50 million for the ....
12. lis 2016
před 10 r.
Kvartální
Divis Laboratories Ltd has announced the following results for the quarter ended June 30, 2016 The Unaudited Standalone results for the Quarter ended June 30, 2016 The Company ....
12. srp 2016
před 10 r.
Výroční
Divis Laboratories Ltd has submitted to BSE a copy of Revised Results Press Release for March 31, 2016.
28. kvě 2016
před 10 r.
Výroční
Annual Report FY2016
28. kvě 2016
před 10 r.
Kvartální
Divis Laboratories Ltd has announced the following Un-Audited Standalone results for the quarter ended December 31, 2015 : The Company has posted a net profit of Rs. 2465.60 million ....
5. úno 2016
před 11 r.
2015
Kvartální
Divis Laboratories Ltd has announced the following Un-Audited Standalone results for the quarter ended September 30, 2015 : The Company has posted a net profit of Rs. 2957.30 million ....
31. říj 2015
před 11 r.
Kvartální
Divis Laboratories Ltd has announced the following results for the quarter ended June 30, 2015 The Unaudited Standalone results for the Quarter ended June 30, 2015: The Company ....
8. srp 2015
před 11 r.
Výroční
Divis Laboratories Ltd has announced the following results for the quarter & year ended March 31, 2015: The Audited results for the Quarter ended March 31, 2015 The Company ....
23. kvě 2015
před 11 r.
Kvartální
Divis Laboratories Ltd has announced the following Unaudited Standalone results for the quarter ended December 31, 2014: The Company has posted a net profit of Rs. 2205.80 million ....
31. led 2015
před 12 r.
Pro zvolenou kategorii nemáme žádné dokumenty.
